Literature DB >> 24980155

Role of CNR1 polymorphisms in moderating the effects of psychosocial adversity on impulsivity in adolescents.

Arlette F Buchmann1, Erika Hohm, Stephanie H Witt, Dorothea Blomeyer, Christine Jennen-Steinmetz, Martin H Schmidt, Günter Esser, Tobias Banaschewski, Daniel Brandeis, Manfred Laucht.   

Abstract

Enhanced endocannabinoid signaling has been implicated in typically adolescent behavioral features such as increased risk-taking, impulsivity and novelty seeking. Research investigating the impact of genetic variants in the cannabinoid receptor 1 gene (CNR1) and of early rearing conditions has demonstrated that both factors contribute to the prediction of impulsivity-related phenotypes. The present study aimed to test the hypothesis of an interaction of the two most studied CNR1 polymorphisms rs806379 and rs1049353 with early psychosocial adversity in terms of affecting impulsivity in 15-year-olds from an epidemiological cohort sample followed since birth. In 323 adolescents (170 girls, 153 boys), problems of impulse control and novelty seeking were assessed using parent-report and self-report, respectively. Exposure to early psychosocial adversity was determined in a parent interview conducted at the age of 3 months. The results indicated that impulsivity increased following exposure to early psychosocial adversity, with this increase being dependent on CNR1 genotype. In contrast, while individuals exposed to early adversity scored higher on novelty seeking, no significant impact of genotype or the interaction thereof was detected. This is the first evidence to suggest that the interaction of CNR1 gene variants with the experience of early life adversity may play a role in determining adolescent impulsive behavior. However, given that the reported findings are obtained in a high-risk community sample, results are restricted in terms of interpretation and generalization. Future research is needed to replicate these findings and to identify the mediating mechanisms underlying this effect.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24980155     DOI: 10.1007/s00702-014-1266-3

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  52 in total

1.  Behavioral sequelae of perinatal insults and early family adversity at 8 years of age.

Authors:  M Laucht; G Esser; L Baving; M Gerhold; I Hoesch; W Ihle; P Steigleider; B Stock; R M Stoehr; D Weindrich; M H Schmidt
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-10       Impact factor: 8.829

2.  Historical development and present status of the schedule for affective disorders and schizophrenia for school-age children (K-SADS).

Authors:  P J Ambrosini
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-01       Impact factor: 8.829

3.  Cannabinoid receptor genotype moderation of the effects of childhood physical abuse on anhedonia and depression.

Authors:  Arpana Agrawal; Elliot C Nelson; Andrew K Littlefield; Kathleen K Bucholz; Louisa Degenhardt; Anjali K Henders; Pamela A F Madden; Nicholas G Martin; Grant W Montgomery; Michele L Pergadia; Kenneth J Sher; Andrew C Heath; Michael T Lynskey
Journal:  Arch Gen Psychiatry       Date:  2012-07

4.  Enhancement of endocannabinoid signalling during adolescence: Modulation of impulsivity and long-term consequences on metabolic brain parameters in early maternally deprived rats.

Authors:  Eva María Marco; Walter Adriani; Rossella Canese; Franca Podo; Maria Paz Viveros; Giovanni Laviola
Journal:  Pharmacol Biochem Behav       Date:  2006-11-13       Impact factor: 3.533

Review 5.  CNR1 gene polymorphisms in addictive disorders: a systematic review and a meta-analysis.

Authors:  Amine Benyamina; Oussama Kebir; Lisa Blecha; Michel Reynaud; Marie-Odile Krebs
Journal:  Addict Biol       Date:  2011-01       Impact factor: 4.280

Review 6.  A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry.

Authors:  Laramie E Duncan; Matthew C Keller
Journal:  Am J Psychiatry       Date:  2011-09-02       Impact factor: 18.112

7.  Temperament in the developmental course: a longitudinal comparison of New York Longitudinal Study-derived dimensions with the Junior Temperament and Character Inventory.

Authors:  Martina Pitzer; Guenter Esser; Martin H Schmidt; Manfred Laucht
Journal:  Compr Psychiatry       Date:  2007-08-21       Impact factor: 3.735

8.  Interacting effects of the dopamine transporter gene and psychosocial adversity on attention-deficit/hyperactivity disorder symptoms among 15-year-olds from a high-risk community sample.

Authors:  Manfred Laucht; Markus H Skowronek; Katja Becker; Martin H Schmidt; Günter Esser; Thomas G Schulze; Marcella Rietschel
Journal:  Arch Gen Psychiatry       Date:  2007-05

9.  Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse.

Authors:  P-W Zhang; H Ishiguro; T Ohtsuki; J Hess; F Carillo; D Walther; E S Onaivi; T Arinami; G R Uhl
Journal:  Mol Psychiatry       Date:  2004-10       Impact factor: 15.992

Review 10.  Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure.

Authors:  Miriam Schneider
Journal:  Addict Biol       Date:  2008-06       Impact factor: 4.280

View more
  9 in total

1.  Cannabinoid CB1 receptor inhibition blunts adolescent-typical increased binge alcohol and sucrose consumption in male C57BL/6J mice.

Authors:  Abigail E Agoglia; Sarah E Holstein; Vallari R Eastman; Clyde W Hodge
Journal:  Pharmacol Biochem Behav       Date:  2016-01-19       Impact factor: 3.533

Review 2.  Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.

Authors:  Daniela Navarro; Ani Gasparyan; Francisco Navarrete; Abraham B Torregrosa; Gabriel Rubio; Marta Marín-Mayor; Gabriela B Acosta; Maria Salud Garcia-Gutiérrez; Jorge Manzanares
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 3.  Early adverse experience and substance addiction: dopamine, oxytocin, and glucocorticoid pathways.

Authors:  Sohye Kim; Stephanie Kwok; Linda C Mayes; Marc N Potenza; Helena J V Rutherford; Lane Strathearn
Journal:  Ann N Y Acad Sci       Date:  2016-08-10       Impact factor: 5.691

4.  Genetic and Environmental Risk Factors for Cannabis Use: Preliminary Results for the Role of Parental Care Perception.

Authors:  Maria Carla Gerra; Matteo Manfredini; Elena Cortese; Maria Caterina Antonioni; Claudio Leonardi; Fernanda Magnelli; Lorenzo Somaini; Subramaniam Jayanthi; Jean Lud Cadet; Claudia Donnini
Journal:  Subst Use Misuse       Date:  2019-01-20       Impact factor: 2.164

5.  Cannabinoid Receptor 1 rs1049353 Variant, Childhood Abuse, and the Heterogeneity of PTSD Symptoms: Results From the National Health and Resilience in Veterans Study.

Authors:  Nachshon Korem; Or Duek; Ke Xu; Ilan Harpaz-Rotem; Robert H Pietrzak
Journal:  Chronic Stress (Thousand Oaks)       Date:  2021-04-29

6.  Gene variants and educational attainment in cannabis use: mediating role of DNA methylation.

Authors:  Maria Carla Gerra; Subramaniam Jayanthi; Matteo Manfredini; Donna Walther; Jennifer Schroeder; Karran A Phillips; Jean Lud Cadet; Claudia Donnini
Journal:  Transl Psychiatry       Date:  2018-01-22       Impact factor: 6.222

Review 7.  Pathways Relating the Neurobiology of Attachment to Drug Addiction.

Authors:  Lane Strathearn; Carol E Mertens; Linda Mayes; Helena Rutherford; Purva Rajhans; Guifeng Xu; Marc N Potenza; Sohye Kim
Journal:  Front Psychiatry       Date:  2019-11-08       Impact factor: 4.157

8.  Association of a Variant of CNR1 Gene Encoding Cannabinoid Receptor 1 With Gilles de la Tourette Syndrome.

Authors:  Natalia Szejko; Jakub Piotr Fichna; Krzysztof Safranow; Tomasz Dziuba; Cezary Żekanowski; Piotr Janik
Journal:  Front Genet       Date:  2020-03-04       Impact factor: 4.599

9.  Do Genes Play a Role in the Decoy Effect?

Authors:  Jianmin Zeng; Xinyi Zhao; Huihui Qin; Xingrong Hou; Qinglin Zhang
Journal:  Front Psychol       Date:  2020-10-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.